$1.21
6.20% today
Nasdaq, Apr 04, 08:17 pm CET
ISIN
US29664W1053
Symbol
ESPR
Sector
Industry

Esperion Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Esperion Therapeutics, Inc. Classifications & Recommendation:

Buy
75%
Hold
13%
Sell
13%

Esperion Therapeutics, Inc. Price Target

Target Price $6.63
Price $1.29
Potential
Number of Estimates 8
8 Analysts have issued a price target Esperion Therapeutics, Inc. 2026 . The average Esperion Therapeutics, Inc. target price is $6.63. This is higher than the current stock price. The highest price target is
$16.00 1,140.31%
register free of charge
, the lowest is .
A rating was issued by 8 analysts: 6 Analysts recommend Esperion Therapeutics, Inc. to buy, 1 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Esperion Therapeutics, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Esperion Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 332.31 343.95
185.66% 3.50%
EBITDA Margin 16.39% 4.99%
112.27% 69.56%
Net Margin -16.50% 2.14%
95.17% 112.97%

8 Analysts have issued a sales forecast Esperion Therapeutics, Inc. 2025 . The average Esperion Therapeutics, Inc. sales estimate is

$344m
Unlock
. This is
3.50% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$421m 26.54%
Unlock
, the lowest is
$245m 26.18%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $332m 185.66%
2025
$344m 3.50%
Unlock
2026
$314m 8.67%
Unlock
2027
$465m 48.06%
Unlock
2028
$567m 21.95%
Unlock
2029
$1.1b 97.55%
Unlock

3 Analysts have issued an Esperion Therapeutics, Inc. EBITDA forecast 2025. The average Esperion Therapeutics, Inc. EBITDA estimate is

$17.2m
Unlock
. This is
68.49% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$49.5m 9.09%
Unlock
, the lowest is
$-26.1m 147.92%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $54.5m 135.05%
2025
$17.2m 68.49%
Unlock
2026
$-21.1m 223.00%
Unlock
2027
$51.4m 343.65%
Unlock
2028
$37.4m 27.30%
Unlock

EBITDA Margin

2024 16.39% 112.27%
2025
4.99% 69.56%
Unlock
2026
-6.72% 234.67%
Unlock
2027
11.06% 264.58%
Unlock
2028
6.59% 40.42%
Unlock

4 Esperion Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Esperion Therapeutics, Inc. net profit estimate is

$7.3m
Unlock
. This is
113.88% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$27.4m 151.85%
Unlock
, the lowest is
$-31.3m 40.73%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-54.8m 86.21%
2025
$7.3m 113.38%
Unlock
2026
$-39.2m 633.65%
Unlock
2027
$200m 610.01%
Unlock
2028
$288m 44.12%
Unlock
2029
$619m 114.97%
Unlock

Net Margin

2024 -16.50% 95.17%
2025
2.14% 112.97%
Unlock
2026
-12.47% 682.71%
Unlock
2027
42.95% 444.43%
Unlock
2028
50.76% 18.18%
Unlock
2029
55.23% 8.81%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.28 0.04
86.21% 114.29%
P/E 34.40
EV/Sales 2.04

4 Analysts have issued a Esperion Therapeutics, Inc. forecast for earnings per share. The average Esperion Therapeutics, Inc. EPS is

$0.04
Unlock
. This is
114.81% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$0.14 151.85%
Unlock
, the lowest is
$-0.16 40.74%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.28 86.21%
2025
$0.04 114.29%
Unlock
2026
$-0.20 600.00%
Unlock
2027
$1.02 610.00%
Unlock
2028
$1.47 44.12%
Unlock
2029
$3.16 114.97%
Unlock

P/E ratio

Current -4.84 281.10%
2025
34.40 810.74%
Unlock
2026
-6.45 118.75%
Unlock
2027
1.26 119.53%
Unlock
2028
0.88 30.16%
Unlock
2029
0.41 53.41%
Unlock

Based on analysts' sales estimates for 2025, the Esperion Therapeutics, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.11 73.19%
2025
2.04 3.32%
Unlock
2026
2.23 9.50%
Unlock
2027
1.51 32.46%
Unlock
2028
1.24 18.00%
Unlock
2029
0.63 49.38%
Unlock

P/S ratio

Current 0.77 80.44%
2025
0.74 3.39%
Unlock
2026
0.81 9.50%
Unlock
2027
0.55 32.46%
Unlock
2028
0.45 18.00%
Unlock
2029
0.23 49.38%
Unlock

Current Esperion Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Mar 20 2025
Citizens Capital Markets
Locked
Locked
Locked Mar 05 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 04 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 11 2025
JMP Securities
Locked
Locked
Locked Feb 11 2025
JMP Securities
Locked
Locked
Locked Jan 23 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 23 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 20 2025
Locked
Citizens Capital Markets:
Locked
Locked
Mar 05 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 04 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 11 2025
Locked
JMP Securities:
Locked
Locked
Feb 11 2025
Locked
JMP Securities:
Locked
Locked
Jan 23 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 23 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today